Sjoukje J C van der Stegen
Overview
Explore the profile of Sjoukje J C van der Stegen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
3236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen S, Hamieh M, Cunanan K, et al.
Nature
. 2017 Feb;
543(7643):113-117.
PMID: 28225754
Chimeric antigen receptors (CARs) are synthetic receptors that redirect and reprogram T cells to mediate tumour rejection. The most successful CARs used to date are those targeting CD19 (ref. 2),...
12.
Zhao Z, Condomines M, van der Stegen S, Perna F, Kloss C, Gunset G, et al.
Cancer Cell
. 2015 Oct;
28(4):415-428.
PMID: 26461090
T cell engineering is a powerful means to rapidly generate anti-tumor T cells. The costimulatory properties of second-generation chimeric antigen receptors (CARs) determine the overall potency of adoptively transferred T...
13.
van der Stegen S, Hamieh M, Sadelain M
Nat Rev Drug Discov
. 2015 Jul;
14(7):499-509.
PMID: 26129802
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation,...
14.
Parente-Pereira A, Shmeeda H, Whilding L, Zambirinis C, Foster J, van der Stegen S, et al.
J Immunol
. 2014 Oct;
193(11):5557-66.
PMID: 25339667
Adoptive immunotherapy using γδ T cells harnesses their natural role in tumor immunosurveillance. The efficacy of this approach is enhanced by aminobisphosphonates such as zoledronic acid and alendronic acid, both...
15.
van der Stegen S, Davies D, Wilkie S, Foster J, Sosabowski J, Burnet J, et al.
J Immunol
. 2013 Sep;
191(9):4589-98.
PMID: 24062490
The ErbB network is dysregulated in many solid tumors. To exploit this, we have developed a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant ErbB dimers. T1E28z...
16.
Parente-Pereira A, Whilding L, Brewig N, van der Stegen S, Davies D, Wilkie S, et al.
J Immunol
. 2013 Jul;
191(5):2437-45.
PMID: 23898037
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, underscoring the need for better therapies. Adoptive immunotherapy using genetically targeted T cells represents a promising new treatment for hematologic...
17.
Wilkie S, van Schalkwyk M, Hobbs S, Davies D, van der Stegen S, Parente Pereira A, et al.
J Clin Immunol
. 2012 Apr;
32(5):1059-70.
PMID: 22526592
Purpose: Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit cytotoxicity and interferon-γ production while the...
18.
Davies D, Foster J, van der Stegen S, Parente-Pereira A, Chiapero-Stanke L, Delinassios G, et al.
Mol Med
. 2012 Feb;
18:565-76.
PMID: 22354215
Pharmacological targeting of individual ErbB receptors elicits antitumor activity, but is frequently compromised by resistance leading to therapeutic failure. Here, we describe an immunotherapeutic approach that exploits prevalent and fundamental...
19.
Meek B, van Elssen C, Huijskens M, van der Stegen S, Tonnaer S, Lumeij S, et al.
BMC Immunol
. 2011 Feb;
12:17.
PMID: 21332988
Background: Haplo-identical hematopoietic stem cell (HSC) transplantation is very successful in eradicating haematological tumours, but the long post-transplant T-lymphopenic phase is responsible for high morbidity and mortality rates. Clark et...
20.
Wilkie S, Burbridge S, Chiapero-Stanke L, Pereira A, Cleary S, van der Stegen S, et al.
J Biol Chem
. 2010 Jun;
285(33):25538-44.
PMID: 20562098
Polyclonal T-cells can be directed against cancer using transmembrane fusion molecules known as chimeric antigen receptors (CARs). Although preclinical studies have provided encouragement, pioneering clinical trials using CAR-based immunotherapy have...